GPP
STML

Great Point Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Great Point Partners’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-475,200
Closed -$4.2M – 32
2015
Q3 		$4.2M Hold
475,200
– – 1.66% 22
2015
Q2 		$5.59M Hold
475,200
– – 2.18% 18
2015
Q1 		$6.88M Buy
+475,200
New +$7.27M 3.03% 13

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's STML Position: Q4 2015 in Review

Great Point Partners sold out of Stemline Therapeutics, Inc. (STML) in Q4 2015, closing a stake of 475,200 shares — an estimated $4.2M sold.

Great Point Partners first reported a position in STML in Q1 2015 and held it in 3 quarters. The position peaked at $6.88M in Q1 2015. 66 funds tracked by Wall St. Rank hold STML as of Q4 2015.

  • Great Point Partners reported no remaining Stemline Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Great Point Partners sold 475,200 Stemline Therapeutics, Inc. shares in Q4 2015, an estimated $4.2M.
  • Great Point Partners first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • Great Point Partners's Stemline Therapeutics, Inc. position peaked at $6.88M in Q1 2015.
  • 66 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2015.

Based on Great Point Partners's 13F filing for Q4 2015, filed 16 Feb 2016.